Form 8-K - Current report:
SEC Accession No. 0001193125-25-047732
Filing Date
2025-03-06
Accepted
2025-03-06 06:05:19
Documents
15
Period of Report
2025-03-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d932746d8k.htm   iXBRL 8-K 49507
2 EX-10.1 d932746dex101.htm EX-10.1 174907
  Complete submission text file 0001193125-25-047732.txt   418184

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dvax-20250305.xsd EX-101.SCH 3876
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dvax-20250305_def.xml EX-101.DEF 13672
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20250305_lab.xml EX-101.LAB 22621
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20250305_pre.xml EX-101.PRE 14640
18 EXTRACTED XBRL INSTANCE DOCUMENT d932746d8k_htm.xml XML 5486
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 25713507
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)